Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL) stock is acting a bit erratic Monday morning, first rising nearly 2% in early trading, and then giving up all its gains and falling into the red. As of 11:05 ...

In that case, investors can buy Alphabet at a steep discount to its peers. If Alphabet had a 30 P/E ratio instead of a sub-20 P/E, it would be worth well over $3 trillion.

Alphabet (GOOG 0.51%) (GOOGL 0.54%) stock is acting a bit erratic Monday morning, first rising nearly 2% in early trading, and then giving up all its gains and falling into the red. As of 11:05 a ...

Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) stock is acting a bit erratic Monday morning, first rising nearly 2% in early trading, and then giving up all its gains and falling into the red. As of 11: ...

Alphabet's revenue and earnings growth are near the top compared to other "Magnificent Seven" stocks. Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) has been one of the most hated big tech stocks in the ...

Below, we present a snapshot of the trends in volume and open interest for calls and puts across Alphabet's significant trades, within a strike price range of $160.0 to $210.0, over the past month.

Alphabet gains regulatory support for AI in search, with Gemini set to boost engagement and revenue amid manageable legal risks. See why GOOG stock is a strong buy.

Like Tesla, Apple could benefit from AI in the near future. But so far, AI simply hasn't been a catalyst for the company in the same way it has for other mega-cap tech-focused companies. Alphabet ...

To me, the deal with OpenAI is a transformative game changer for Alphabet in the long run and I see the stock as a no-brainer buy right now. Should you invest $1,000 in Alphabet right now?

Apple's stock trades at a far higher premium than Alphabet's, and Alphabet's stock is actually cheaper than the S&P 500 (SNPINDEX: ^GSPC), which trades for 22.8 times forward earnings.

The reason Alphabet's stock has a far lower valuation relative to its Big Tech peers is that investors expect Google search's revenue growth to decelerate significantly in the near to medium term ...

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery.